The Goldman Sachs Group Forecasts Strong Price Appreciation for MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock

Key Points

• The Goldman Sachs Group has raised the price target for MoonLake Immunotherapeutics from $74.00 to $82.00, indicating a potential upside of 56.89% from its previous close.
• MoonLake has received a mix of ratings from other analysts, with seven ratings as "buy" and an average target price of $74.43.
• The company recently reported an EPS of ($0.87), missing analysts' expectations, and forecasts a projected EPS of -1.79 for the current year.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) had its target price increased by The Goldman Sachs Group from $74.00 to $82.00 in a research note issued to investors on Wednesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other equities analysts also recently commented on MLTX. Wedbush restated an "outperform" rating and set a $80.00 price objective (up from $78.00) on shares of MoonLake Immunotherapeutics in a research note on Tuesday, May 13th. Rothschild & Co Redburn initiated coverage on shares of MoonLake Immunotherapeutics in a research note on Monday, July 28th. They issued a "neutral" rating and a $65.00 target price for the company. Needham & Company LLC reiterated a "buy" rating and issued a $66.00 target price on shares of MoonLake Immunotherapeutics in a research note on Tuesday, May 13th. Wolfe Research upgraded shares of MoonLake Immunotherapeutics from a "peer perform" rating to an "outperform" rating and set a $61.00 target price for the company in a research note on Monday, May 19th. Finally, Royal Bank Of Canada reiterated an "outperform" rating and issued a $67.00 target price on shares of MoonLake Immunotherapeutics in a research note on Tuesday, June 3rd. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, MoonLake Immunotherapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $74.43.

MoonLake Immunotherapeutics Trading Up 1.0%

NASDAQ MLTX traded up $0.51 on Wednesday, reaching $52.40. The company had a trading volume of 274,326 shares, compared to its average volume of 506,376. The company has a debt-to-equity ratio of 0.21, a current ratio of 16.65 and a quick ratio of 16.65. MoonLake Immunotherapeutics has a 1-year low of $31.42 and a 1-year high of $58.26. The company's fifty day moving average is $48.87 and its 200-day moving average is $43.11.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported ($0.87) earnings per share for the quarter, missing analysts' consensus estimates of ($0.73) by ($0.14). During the same period in the previous year, the business earned ($0.39) EPS. Research analysts forecast that MoonLake Immunotherapeutics will post -1.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of MLTX. Deutsche Bank AG increased its holdings in shares of MoonLake Immunotherapeutics by 59.8% during the fourth quarter. Deutsche Bank AG now owns 903 shares of the company's stock worth $49,000 after purchasing an additional 338 shares during the period. Geode Capital Management LLC boosted its position in MoonLake Immunotherapeutics by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 58,950 shares of the company's stock valued at $3,192,000 after buying an additional 540 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of MoonLake Immunotherapeutics by 8.2% during the first quarter. PNC Financial Services Group Inc. now owns 9,200 shares of the company's stock worth $359,000 after purchasing an additional 700 shares during the period. MPM Bioimpact LLC lifted its holdings in shares of MoonLake Immunotherapeutics by 0.3% during the first quarter. MPM Bioimpact LLC now owns 316,049 shares of the company's stock worth $12,348,000 after purchasing an additional 819 shares during the period. Finally, US Bancorp DE lifted its holdings in shares of MoonLake Immunotherapeutics by 114.4% during the first quarter. US Bancorp DE now owns 2,208 shares of the company's stock worth $86,000 after purchasing an additional 1,178 shares during the period. 93.85% of the stock is owned by institutional investors.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.